Last reviewed · How we verify

NCT02473419: VAYA-fMRI

Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

Completed Last updated 24 March 2017
What this trial tests

trial testing Vayarin in ADHD in 107 participants. Completed in 2 March 2017.

Timeline
1 May 2015
Primary endpoint
2 March 2017
2 March 2017

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
StatusCompleted
Study typeOBSERVATIONAL
Enrollment107
Start date1 May 2015
Primary completion2 March 2017
Estimated completion2 March 2017
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 18 to 60, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The objective of this research is to use functional magnetic resonance imaging (fMRI) with a neuropsychological task to test the prefrontal mechanism of action of the medical food Vayarin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vayarin

Trials testing the same drug.

Other recruiting trials for ADHD

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02473419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing